A Phase 2 Randomized, Double-Masked Placebo-Controlled Crossover Safety and Tolerability Study of Ataluren for Drug Resistant Epilepsy in Patients With Nonsense Mutation CDKL5 or Dravet Syndrome
Latest Information Update: 17 Feb 2023
Price :
$35 *
At a glance
- Drugs Ataluren (Primary)
- Indications Dravet syndrome; Early infantile epileptic encephalopathy 2
- Focus Proof of concept; Therapeutic Use
- 07 Sep 2021 Status changed from active, no longer recruiting to completed.
- 22 Oct 2020 Planned End Date changed from 1 Dec 2022 to 1 Mar 2021.
- 22 Oct 2020 Planned primary completion date changed from 1 Dec 2021 to 1 Jan 2021.